Health · Healthcare & Policy · 1 hr ago

Brazil’s Anvisa weighs limits on clinics using compounded weight-loss drugs

Brazil’s Anvisa weighs limits on clinics using compounded weight-loss drugs

Brazil’s health regulator, Anvisa, is set to consider new rules for compounded weight-loss drugs on Wednesday.

The proposal would stop compounding pharmacies from supplying these medicines to clinics and other third parties for stock, patient injections or resale.

It would also bar pharmacies from building large stocks in advance and from advertising the products to drive prescriptions or sales.

Patients could still take an individual prescription directly to a pharmacy, if a doctor decides a custom formula is needed.

The debate follows a joint statement by Anvisa and federal police in May that said they had found volumes of compounded doses inconsistent with the rules and signs of complex organized crime.

The proposal aims to limit how these products are supplied and promoted, while the discussion comes amid pressure for wider access to obesity medicines.

Anvisa’s board is due to analyze the proposal next, but the sources do not say when a final decision would take effect.

1 source

Related

What people are saying

Alexandre PadilhaBrazil’s health minister
organize the debate
via Folha
offering customized, individualized doses, which sometimes the medical professional wants but the industry does not produce
via Folha